DMD Therapeutics Company
DMD Therapeutics intends to use the funds to move DMD-813 into drug development for the treatment of Duchenne Muscular Dystrophy.
Technology:
Drug Delivery
Industry:
PharmTech
Headquarters:
Seattle, Washington, United States
Founded Date:
2016
Employees Number:
1-10
Funding Status:
Seed
Register and Claim Ownership